Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q2 EPS of ($0.94), $0.08 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $390 thousand versus the consensus estimate of $467.27 thousand.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.